Tyra Biosciences Inc. has announced the initiation of BEACH301, a Phase 2 clinical study focused on evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib is a potentially first-in-class, once-daily oral FGFR3-selective inhibitor, developed using Tyra's SNÅP platform. As of now, the first child has been dosed in the study. Initial results from the safety sentinel cohort of the trial are anticipated to be available in the second half of 2026. Tyra Biosciences emphasizes that dabogratinib is the only oral FGFR3-selective inhibitor currently in clinical development for achondroplasia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA55524) on August 21, 2025, and is solely responsible for the information contained therein.